American Journal of Cardiovascular Drugs

, Volume 2, Issue 1, pp 23–35

Drug Treatment of Orthostatic Hypotension Because of Autonomic Failure or Neurocardiogenic Syncope

Therapy in Practice


Orthostatic hypotension either because of autonomic failure or neurocardiogenic syncope can be very incapacitating and should be treated accordingly. Drug therapy is frequently needed to alleviate orthostatic symptoms. The physiopathological basis of neurocardiogenic syncope and of autonomic failure is completely different and their treatment should be distinct.

In the past 5 years, many randomized, placebo-controlled trials have shed light on the efficacy of specific pressor drugs. In patients with orthostatic hypotension because of autonomic failure, α-adrenoceptor agonists, and midodrine in particular, have been shown to increase standing blood pressure and decrease orthostatic symptoms. Other drugs such as octreotide, indomethacin or ergotamine have also been shown to elevate standing blood pressure and/or orthostatic tolerance. Fludrocortisone is a well known and frequently used pressor drug but randomized controlled studies are needed to measure its efficacy. In patients with orthostatic hypotension associated with neurocardiogenic syncope, clinical trials have demonstrated that β-blockers, especially β1-selective agents without intrinsic sympathomimetic activity such as atenolol, midodrine and paroxetine can decrease recurrence of syncope.

Treatment algorithms, such as those presented in this review, should always be interpreted in the light of individual patient characteristics. Many of the drugs used for orthostatic hypotension have multiple indications and contraindications that should influence therapeutic decisions. Little is known about the effectiveness and tolerability of specific combinations of pressor drugs. Consequently, sound clinical judgment and close follow-up of patients should always guide combination therapy.


  1. 1.
    Grubb BP. Pathophysiology and differential diagnosis of neurocardiogenic syncope. Am J Cardiol 1999; 84(8A): 3Q–9QPubMedCrossRefGoogle Scholar
  2. 2.
    Lamarre-Cliche M, Cusson J. The fainting patient: value of the head-upright tilt-table test in adult patients with orthostatic intolerance. CMAJ 2001; 164(3): 372–6PubMedGoogle Scholar
  3. 3.
    Abboud FM. Neurocardiogenic syncope. N Engl J Med 1993; 328(15): 1117–20PubMedCrossRefGoogle Scholar
  4. 4.
    Mtinangi BL, Hainsworth R. Early effects of oral salt on plasma volume, orthostatic tolerance, and baroreceptor sensitivity in patients with syncope. Clin Auton Res 1998; 8(4): 231–5PubMedCrossRefGoogle Scholar
  5. 5.
    Denq JC, Opfer-Gehrking TL, Giuliani M, et al. Efficacy of compression of different capacitance beds in the amelioration of orthostatic hypotension. Clin Auton Res 1997; 7(6): 321–6PubMedCrossRefGoogle Scholar
  6. 6.
    Henry R, Rowe J, O’Mahony D. Haemodynamic analysis of efficacy of compression hosiery in elderly fallers with orthostatic hypotension. Lancet 1999; 354(9172): 45–6PubMedCrossRefGoogle Scholar
  7. 7.
    Ten Harkel AD, Van Lieshout JJ, Wieling W. Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J Intern Med 1992; 232(2): 139–45PubMedCrossRefGoogle Scholar
  8. 8.
    Kardos A, Avramov K, Dongo A, et al. Management of severe orthostatic hypotension by head-up-tilt posture and administration of fludrocortisone. Orv Hetil 1996; 137(43): 2407–11PubMedGoogle Scholar
  9. 9.
    Hoeldtke RD, Cavanaugh ST, Hughes JD. Treatment of orthostatic hypotension: interaction of pressor drugs and tilt table conditioning. Arch Phys Med Rehabil 1988; 69(10): 895–8PubMedGoogle Scholar
  10. 10.
    Di Girolamo E, Di Iorio C, Leonzio L, et al. Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents: a controlled study. Circulation 1999; 100(17): 1798–801PubMedCrossRefGoogle Scholar
  11. 11.
    Bouvette CM, McPhee BR, Opfer-Gehrking TL, et al. Role of physical countermaneuvers in the management of orthostatic hypotension: efficacy and biofeedback augmentation. Mayo Clin Proc 1996; 71(9): 847–53PubMedCrossRefGoogle Scholar
  12. 12.
    Connolly SJ, Sheldon R, Roberts RS, et al. The North American Vasovagal Pacemaker Study (VPS): a randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol 1999; 33(1): 16–20PubMedCrossRefGoogle Scholar
  13. 13.
    Abe H, Numata T, Hanada H, et al. Successful treatment of severe orthostatic hypotension with cardiac tachypacing in dual chamber pacemakers. Pacing Clin Electrophysiol 2000; 23(1): 137–9PubMedCrossRefGoogle Scholar
  14. 14.
    Natale A, Sra J, Dhala A, et al. Efficacy of different treatment strategies for neurocardiogenic syncope. Pacing Clin Electrophysiol 1995; 18(4 Pt 1): 655–62PubMedCrossRefGoogle Scholar
  15. 15.
    Shannon J, Jordan J, Costa F, et al. The hypertension of autonomic failure and its treatment. Hypertension 1997; 30(5): 1062–7PubMedCrossRefGoogle Scholar
  16. 16.
    Bessa AM, Zanella MT, Saragoca MA, et al. Acute hemodynamic and humoral effects of metoclopramide on blood pressure control improvement in subjects with diabetic orthostatic hypotension. Clin Pharmacol Ther 1984; 36(6): 738–44PubMedCrossRefGoogle Scholar
  17. 17.
    Peroutka SJ. Drugs effective in the therapy of migraine. In: Hardman JG, Limbird LE, editors. Goodman & Gilma’s The pharmacological basis of therapeutics. 9th ed. New York: McGraw Hill 1995: 487–502Google Scholar
  18. 18.
    Chobanian AV, Tifft CP, Faxon DP, et al. Treatment of chronic orthostatic hypotension with ergotamine. Circulation 1983; 67(3): 602–9PubMedCrossRefGoogle Scholar
  19. 19.
    Sung BH, Lovallo WR, Pincomb GA, et al. Effects of caffeine on blood pressure response during exercise in normotensive healthy young men. Am J Cardiol 1990; 65(13): 909–13PubMedCrossRefGoogle Scholar
  20. 20.
    McClellan KJ, Wiseman LR, Wilde ML Midodrine: a review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging 1998; 12(1): 76–86PubMedCrossRefGoogle Scholar
  21. 21.
    Hoeldtke RD, Davis KM, Joseph J, et al. Hemodynamic effects of octreotide in patients with autonomic neuropathy. Circulation 1991; 84(1): 168–76PubMedCrossRefGoogle Scholar
  22. 22.
    Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998; 51(1): 120–4PubMedCrossRefGoogle Scholar
  23. 23.
    Scherzinger SS, Dowse R, Kanfer I. Steady state pharmacokinetics and dose-proportionality of phenylpropanolamine in healthy subjects. J Clin Pharmacol 1990; 30(4): 372–7PubMedGoogle Scholar
  24. 24.
    Jordan J, Shannon JR, Biaggioni I, et al. Contrasting actions of pressor agents in severe autonomic failure. Am J Med 1998; 105(2): 116–24PubMedCrossRefGoogle Scholar
  25. 25.
    Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993; 95(1): 38–48PubMedCrossRefGoogle Scholar
  26. 26.
    Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997; 277(13): 1046–51PubMedCrossRefGoogle Scholar
  27. 27.
    Biaggioni I, Onrot J, Stewart CK, et al. The potent pressor effect of phenylpropanolamine in patients with autonomic impairment. JAMA 1987; 258(2): 236–9PubMedCrossRefGoogle Scholar
  28. 28.
    Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343(25): 1826–32PubMedCrossRefGoogle Scholar
  29. 29.
    Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology 1999; 53(9): 2151–7PubMedCrossRefGoogle Scholar
  30. 30.
    Mathias CJ, Bannister RB, Cortelli P, et al. Clinical, autonomic and therapeutic observations in two siblings with postural hypotension and sympathetic failure due to an inability to synthesize noradrenaline from dopamine because of a deficiency of dopamine beta hydroxylase. Q J Med 1990; 75(278): 617–33PubMedGoogle Scholar
  31. 31.
    Gentric A, Fouilhoux A, Caroff M, et al. Dopamine B hydroxylase deficiency responsible for severe dysautonomic orthostatic hypotension in an elderly patient. J Am Geriatr Soc 1993; 41(5): 550–1PubMedGoogle Scholar
  32. 32.
    Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med 1995; 99(6): 604–10PubMedCrossRefGoogle Scholar
  33. 33.
    Chobanian AV, Volicer L, Tifft CP, et al. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med 1979; 301(2): 68–73PubMedCrossRefGoogle Scholar
  34. 34.
    Pirpiris M, Sudhir K, Yeung S, et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19(6 Pt 1): 567–74PubMedCrossRefGoogle Scholar
  35. 35.
    Pirpiris M, Cox H, Esler M, et al. Mineralocorticoid induced hypertension and noradrenaline spillover in man. Clin Exp Hypertens 1994; 16(2): 147–61PubMedCrossRefGoogle Scholar
  36. 36.
    Campbell IW, Ewing DJ, Clarke BE Therapeutic experience with fludrocortisone in diabetic postural hypotension. BMJ 1976; 1(6014): 872–4PubMedCrossRefGoogle Scholar
  37. 37.
    Matsubara S, Sawa Y, Yokoji H, et al. Shy-Drager syndrome: effect of fludrocortisone and L-threo-3,4-dihydroxyphenylserine on the blood pressure and regional cerebral blood flow. J Neurol Neurosurg Psychiatry 1990; 53(11): 994–7PubMedCrossRefGoogle Scholar
  38. 38.
    Kaufmann H, Brannan T, Krakoff L, et al. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 1988; 38(6): 951–6PubMedCrossRefGoogle Scholar
  39. 39.
    Hussain RM, McIntosh SJ, Lawson J, et al. Fludrocortisone in the treatment of hypotensive disorders in the elderly. Heart 1996; 76(6): 507–9PubMedCrossRefGoogle Scholar
  40. 40.
    Insel PA. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardmann JG, Limbird LE, editors. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1995: 617–658Google Scholar
  41. 41.
    Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153(4): 477–84PubMedCrossRefGoogle Scholar
  42. 42.
    Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121(4): 289–300PubMedGoogle Scholar
  43. 43.
    Davies IB, Bannister R, Hensby C, et al. The pressor actions of noradrenaline and angiotension II in chronic autonomic failure treated with indomethacin. Br J Clin Pharmacol 1980; 10(3): 223–9PubMedCrossRefGoogle Scholar
  44. 44.
    Abate G, Polimeni RM, Cuccurullo F, et al. Effects of indomethacin on postural hypotension in Parkinsonism. BMJ 1979; 2(6203): 1466–8PubMedCrossRefGoogle Scholar
  45. 45.
    Kochar MS, Itskovitz HD. Treatment of idiopathic orthostatic hypotension (Shy-Drager syndrome) with indomethacin. Lancet 1978; I(8072): 1011–4CrossRefGoogle Scholar
  46. 46.
    Saxena PR. Cardiovascular effects from stimulation of 5-hydroxytryptamine receptors. Fundam Clin Pharmacol 1989; 3(3): 245–65PubMedCrossRefGoogle Scholar
  47. 47.
    Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998; 155(5): 660–5PubMedGoogle Scholar
  48. 48.
    Grubb BP, Samoil D, Kosinski D, et al. E. Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension. Am J Med 1994; 97(4): 366–8PubMedCrossRefGoogle Scholar
  49. 49.
    Montastruc JL, Pelat M, Verwaerde P, et al. Fluoxetine in orthostatic hypotension of Parkinson’s disease: a clinical and experimental pilot study. Fundam Clin Pharmacol 1998; 12(4): 398–402PubMedCrossRefGoogle Scholar
  50. 50.
    Hoeldtke RD, Cavanaugh ST, Hughes JD, et al. Treatment of orthostatic hypotension with dihydroergotamine and caffeine. Ann Intern Med 1986; 105(2): 168–73PubMedGoogle Scholar
  51. 51.
    Biaggioni I, Zygmunt D, Haile V, et al. Pressor effect of inhaled ergotamine in orthostatic hypotension. Am J Cardiol 1990; 65(1): 89–92PubMedCrossRefGoogle Scholar
  52. 52.
    Dewey RB, Rao SD, Holmburg SL, et al. Ergotamine/caffeine treatment of orthostatic hypotension in parkinsonism with autonomic failure. Eur J Neurol 1998; 5(6): 593–9PubMedCrossRefGoogle Scholar
  53. 53.
    Muhlberger V, Abbrederis K, Knapp E. Myocardial infarct during ergotamine medication in a young man with normal coronary arteries. Dtsch Med Wochenschr 1983; 108(16): 623–6PubMedCrossRefGoogle Scholar
  54. 54.
    Rem JA, Gratzl O, Follath F, et al. Acute myocardial infarct after prophylactic administration of low doses of heparin-ergotamine: coronary artery spasm the cause?. Schweiz Med Wochenschr 1986; 116(51): 1814–6PubMedGoogle Scholar
  55. 55.
    Grand A, Fournier E, Barraud P, et al. Vasospastic angina with angiographically normal coronary vessels of iatrogenic origin: apropos of 2 cases. Ann Cardiol Angeiol (Paris) 1992; 41(1): 39–46Google Scholar
  56. 56.
    Pincomb GA, Lovallo WR, Passey RB, et al. Effects of caffeine on vascular resistance, cardiac output and myocardial contractility in young men. Am J Cardiol 1985; 56(1): 119–22PubMedCrossRefGoogle Scholar
  57. 57.
    Onrot J, Goldberg MR, Biaggioni I, et al. Hemodynamic and humoral effects of caffeine in autonomic failure: therapeutic implications for postprandial hypotension. N Engl J Med 1985; 313(9): 549–54PubMedCrossRefGoogle Scholar
  58. 58.
    Heseltine D, Dakkak M, Woodhouse K, et al. The effect of caffeine on postprandial hypotension in the elderly. J Am Geriatr Soc 1991; 39(2): 160–4PubMedGoogle Scholar
  59. 59.
    Dews PB, Curtis GL, Hanford KJ, et al. The frequency of caffeine withdrawal in a population-based survey and in a controlled, blinded pilot experiment. J Clin Pharmacol 1999; 39(12): 1221–32PubMedCrossRefGoogle Scholar
  60. 60.
    Biaggioni I, Robertson D, Krantz S, et al. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med 1994; 121(3): 181–6PubMedGoogle Scholar
  61. 61.
    Hoeldtke RD, Streeten DH. Treatment of orthostatic hypotension with erythropoietin. N Engl J Med 1993; 329(9): 611–5PubMedCrossRefGoogle Scholar
  62. 62.
    Cooper AM, Braatvedt GD, Qamar MI, et al. Fasting and post-prandial splanchnic blood flow is reduced by a somatostatin analogue (octreotide) in man. Clin Sci (Colch) 1991; 81(2): 169–75Google Scholar
  63. 63.
    Hoeldtke RD, Horvath GG, Bryner KD, et al. Treatment of orthostatic hypotension with midodrine and octreotide. J Clin Endocrinol Metab 1998; 83(2): 339–43PubMedCrossRefGoogle Scholar
  64. 64.
    Wood SM, Kraenzlin ME, Adrian TE, et al. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue, symptomatic and peptide responses. Gut 1985; 26(5): 438–44PubMedCrossRefGoogle Scholar
  65. 65.
    Williams G, Anderson JV, Williams SJ, et al. Clinical evaluation of SMS 201–995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion. Acta Endocrinol Suppl 1987; 286: 26–36Google Scholar
  66. 66.
    Hoeldtke RD, O’Dorisio TM, Boden G. Treatment of autonomic neuropathy with a somatostatin analogue SMS-201–995. Lancet 1986; II(8507): 602–5CrossRefGoogle Scholar
  67. 67.
    Hoeldtke RD, Israel BC. Treatment of orthostatic hypotension with octreotide. J Clin Endocrinol Metab 1989; 68(6): 1051–9PubMedCrossRefGoogle Scholar
  68. 68.
    Bordet R, Benhadjali J, Destee A, et al. Octreotide effects on orthostatic hypotension in patients with multiple system atrophy: a controlled study of acute administration. Clin Neuropharmacol 1995; 18(1): 83–9PubMedCrossRefGoogle Scholar
  69. 69.
    Woo J, Or KK, Nicholls MG. Lack of efficacy of octreotide in the long term treatment of orthostatic hypotension. Aust N Z J Med 1992; 22(1): 83–4PubMedCrossRefGoogle Scholar
  70. 70.
    Robertson D, Goldberg MR, Tung CS, et al. Use of alpha 2 adrenoreceptor agonists and antagonists in the functional assessment of the sympathetic nervous system. J Clin Invest 1986; 78(2): 576–81PubMedCrossRefGoogle Scholar
  71. 71.
    Onrot J, Goldberg MR, Biaggioni I, et al. Oral yohimbine in human autonomic failure. Neurology 1987; 37(2): 215–20PubMedCrossRefGoogle Scholar
  72. 72.
    Robertson D, Goldberg MR, Hollister AS, et al. Clonidine raises blood pressure in severe idiopathic orthostatic hypotension. Am J Med 1983; 74(2): 193–200PubMedCrossRefGoogle Scholar
  73. 73.
    Beretta-Piccoli C, Weidmann P. Metoclopramide alone or combined with flurbiprofen in the treatment of orthostatic hypotension associated with diabetes mellitus. Klin Wochenschr 1982; 60(16): 863–5PubMedCrossRefGoogle Scholar
  74. 74.
    Takeda R, Takeda Y, Koshida H, et al. Effect of metoclopramide on orthostatic hypotension in diabetes mellitus: failure to demonstrate the role of vasoconstrictive hormones. Exp Clin Endocrinol 1988; 91(2): 197–201PubMedCrossRefGoogle Scholar
  75. 75.
    Cleophas TJ, Kauw FH, Bijl C, et al. Effects of beta adrenergic receptor agonists and antagonists in diabetics with symptoms of postural hypotension: a double-blind, placebo-controlled study. Angiology 1986; 37(11): 855–62PubMedCrossRefGoogle Scholar
  76. 76.
    Vagaonescu TD, Saadia D, Tuhrim S, et al. Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet 2000; 355(9205): 725–6PubMedCrossRefGoogle Scholar
  77. 77.
    Jordan J, Shannon JR, Pohar B, et al. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol 1999; 10(1): 35–42PubMedGoogle Scholar
  78. 78.
    Ruiz GA, Peralta A, Gonzalez-Zuelgaray J, et al. Evolution of patients with clinical neurocardiogenic (vasovagal) syncope not subjected to specific treatment. Am Heart J 1995; 130(2): 345–50PubMedCrossRefGoogle Scholar
  79. 79.
    Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340(17): 1321–8PubMedCrossRefGoogle Scholar
  80. 80.
    Leor J, Rotstein Z, Vered Z, et al. Absence of tachycardia during tilt test predicts failure of beta- blocker therapy in patients with neurocardiogenic syncope. Am Heart J 1994; 127(6): 1539–43PubMedCrossRefGoogle Scholar
  81. 81.
    Milstein S, Buetikofer J, Dunnigan A, et al. Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia. Am J Cardiol 1990; 65(20): 1339–44PubMedCrossRefGoogle Scholar
  82. 82.
    Jhamb DK, Singh B, Sharda B, et al. Comparative study of the efficacy of metoprolol and verapamil in patients with syncope and positive head-up tilt test response. Am Heart J 1996; 132(3): 608–11PubMedCrossRefGoogle Scholar
  83. 83.
    Willenbrock R, Ozcelik C, Osterziel KJ, et al. Angiotensin-converting enzyme inhibition, autonomic activity, and hemodynamics in patients with heart failure who perform isometric exercise. Am Heart J 1996; 131(5): 999–1006PubMedCrossRefGoogle Scholar
  84. 84.
    Grubb BP, Wolfe DA, Samoil D, et al. Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope. Pacing Clin Electrophysiol 1993; 16(3 Pt 1): 458–64PubMedCrossRefGoogle Scholar
  85. 85.
    Klingenheben T, Credner S, Hohnloser SH. Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: midodrine as second line treatment in patients refractory to beta-blockers. Pacing Clin Electrophysiol 1999; 22(2): 276–81PubMedCrossRefGoogle Scholar
  86. 86.
    Grubb BP, Kosinski D, Mouhaffel A, et al. The use of methylphenidate in the treatment of refractory neurocardiogenic syncope. Pacing Clin Electrophysiol 1996; 19(5): 836–40PubMedCrossRefGoogle Scholar
  87. 87.
    Cox MM, Perlman BA, Mayor MR, et al. Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope. J Am Coll Cardiol 1995; 26(5): 1293–8PubMedCrossRefGoogle Scholar
  88. 88.
    Mahanonda N, Bhuripanyo K, Kangkagate C, et al. Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results. Am Heart J 1995; 130(6): 1250–3PubMedCrossRefGoogle Scholar
  89. 89.
    Biffi M, Boriani G, Sabbatani P, et al. Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine. Heart 1997; 77(3): 268–72PubMedCrossRefGoogle Scholar
  90. 90.
    Vincenti A, Schena F, Ciro A, et al. Predictors of tilting test negativization during beta-blocker treatment in patients with neurocardiogenic syncope. Cardiologia 1999; 44(5): 461–8PubMedGoogle Scholar
  91. 91.
    Mosqueda-Garcia R, Fernandez-Violante R, Tank J, et al. Yohimbine in neurally mediated syncope: pathophysiological implications. J Clin Invest 1998; 102(10): 1824–30PubMedCrossRefGoogle Scholar
  92. 92.
    Ward CR, Gray JC, Gilroy JJ, et al. Midodrine: a role in the management of neurocardiogenic syncope. Heart 1998; 79(1): 45–9PubMedGoogle Scholar
  93. 93.
    Sra J, Maglio C, Biehl M, et al. Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy. J Cardiovasc Electrophysiol 1997; 8(1): 42–6PubMedCrossRefGoogle Scholar
  94. 94.
    Grubb BP, Karas B, Kosinski D, et al. Preliminary observations on the use of midodrine hydrochloride in the treatment of refractory neurocardiogenic syncope. J Interv Card Electrophysiol 1999; 3(2): 139–43PubMedCrossRefGoogle Scholar
  95. 95.
    Raviele A, Brignole M, Sutton R, et al. Effect of etilefrine in preventing syncopal recurrence in patients with vasovagal syncope: a double-blind, randomized, placebo-controlled trial. The Vasovagal Syncope International Study. Circulation 1999; 99(11): 1452–7PubMedCrossRefGoogle Scholar
  96. 96.
    Rowe PC, Calkins H, DeBusk K, et al. Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. JAMA 2001; 285(1): 52–9PubMedCrossRefGoogle Scholar
  97. 97.
    Grubb BP, Samoil D, Kosinski D, et al. Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents. J Am Coll Cardiol 1994; 24(2): 490–4PubMedCrossRefGoogle Scholar
  98. 98.
    Di Girolamo E, Di Iorio C, Sabatini P, et al. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999; 33(5): 1227–30PubMedCrossRefGoogle Scholar
  99. 99.
    Athyros VG, Didangelos TP, Karamitsos DT, et al. Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy. Acta Cardiol 1998; 53(4): 201–9PubMedGoogle Scholar
  100. 100.
    Zeng C, Zhu Z, Liu G, et al. Randomized, double-blind, placebo-controlled trial of oral enalapril in patients with neurally mediated syncope. Am Heart J 1998; 136(5): 852–8PubMedCrossRefGoogle Scholar
  101. 101.
    Morillo CA, Leitch JW, Yee R, et al. A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt. J Am Coll Cardiol 1993; 22(7): 1843–8PubMedCrossRefGoogle Scholar
  102. 102.
    Nelson SD, Stanley M, Love CJ, et al. The autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope. Arch Intern Med 1991; 151(12): 2425–9PubMedCrossRefGoogle Scholar
  103. 103.
    Lee TM, Su SF, Chen MF, et al. Usefulness of transdermal scopolamine for vasovagal syncope. Am J Cardiol 1996; 78(4): 480–2PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Hôpital Européen Georges Pompidou Centre d’Investigations CliniquesParisFrance

Personalised recommendations